TABLE 1.
Active MSC clinical trials for COVID‐19 as listed at www.ClinicalTrials.gov (accessed on September 30, 2020)
| ClinicalTrials.gov identifier | Study title | Stem cell type | Dosing regimen | Injection route | MSC status | Clinical phase | Status |
|---|---|---|---|---|---|---|---|
| NCT04313322 | Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells | Wharton's jelly MSC | 1 × 106 cells/kg | IV | Native | I | Recruiting |
| NCT04428801 | Autologous adipose‐derived stem cells (AdMSCs) for COVID‐19 | Adipose MSC | 200 × 106 | IV | Native | II | Not yet recruiting |
| NCT04336254 | Safety and efficacy study of allogeneic human dental pulp mesenchymal stem cells to treat severe COVID‐19 patients | Dental pulp MSC | 3 × 107 | IV | Native | I/ II | Recruiting |
| NCT04429763 | Safety and efficacy of mesenchymal stem cells in the management of severe COVID‐19 pneumonia | Bone marrow MSC | 1 × 106 cells/kg | IV | Native | II | Not yet recruiting |
| NCT04416139 | Mesenchymal stem cell for acute respiratory distress syndrome due to COVID‐19 | Bone marrow MSC | 1 × 106 cells/ kg | IV | Native | II | Recruiting |
| NCT04315987 | NestaCell mesenchymal stem cell to treat patients with severe COVID‐19 pneumonia | NestaCell | 20 × 106 cells | IV | Modified | II | Not yet recruiting |
| NCT04348435 | A randomized, double‐blind, placebo‐controlled clinical trial to determine the safety and efficacy of hope biosciences allogeneic mesenchymal stem cell therapy (HB‐adMSCs) to provide protection against COVID‐19 | Adipose MSC | 200 × 106 cells | IV | Modified | II | Enrolling by invitation |
| NCT04366323 | Clinical Trial to assess the safety and efficacy of intravenous administration of allogeneic adult mesenchymal stem cells of expanded adipose tissue in patients with severe pneumonia due to COVID‐19 | Bone marrow MSC | 80 × 106 cells | IV | Native | II | Recruiting |
| NCT04349631 | A Clinical Trial to determine the safety and efficacy of hope biosciences autologous mesenchymal stem cell therapy (HB‐adMSCs) to provide protection against COVID‐19 | Adipose MSC | Not mentioned | IV | Native | II | Enrolling by invitation |
| NCT04302519 | Novel Coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells | Dental pulp MSC | 1 × 106 cells /kg | IV | Native | I | Not yet recruiting |
| NCT04252118 | Mesenchymal stem cell treatment for pneumonia patients infected with COVID‐19 | Bone marrow MSC | 3 × 107 cells | IV | Native | I | Recruiting |
| NCT04346368 | Bone marrow‐derived mesenchymal stem cell treatment for severe patients with coronavirus disease 2019 (COVID‐19) | Bone marrow MSC | 1 × 106 cells/kg | IV | Native | I/ II | Not yet recruiting |
| NCT04288102 | Treatment with human umbilical cord‐derived mesenchymal stem cells for severe corona virus disease 2019 (COVID‐19) | Umbilical cord MSC | 4 × 107 cells | IV | Native | II | Active, not recruiting |
| NCT04273646 | Study of human umbilical cord mesenchymal stem cells in the treatment of severe COVID‐19 | Umbilical cord MSC | 5 × 106 cells/kg | IV | Native | Not applicable | Not yet recruiting |
| NCT04437823 | Efficacy of intravenous infusions of stem cells in the treatment of COVID‐19 patients | Bone marrow MSC | 5 × 105 cells/ kg | IV | Native | II | Recruiting |
| NCT04339660 | Clinical research of human mesenchymal stem cells in the treatment of COVID‐19 pneumonia | Umbilical cord MSCs | 1 × 106 cells/kg | IV | Native | I/ II | Recruiting |
| NCT04382547 | Treatment of COVID‐19 associated pneumonia with allogenic pooled olfactory mucosa‐derived mesenchymal stem cells | Olfactory mucosa MSC | Not mentioned | IV | Native | I/ II | Enrolling by invitation |
| NCT04371601 | Safety and effectiveness of mesenchymal stem cells in the treatment of pneumonia of coronavirus disease 2019 | Bone marrow MSC | 1 × 106 cells /kg | IV | Native | I | Active, not recruiting |
| NCT04366063 | Mesenchymal stem cell therapy for SARS‐CoV‐2‐related acute respiratory distress syndrome | Bone marrow MSC | 100 × 106 MSCs and extracellular vesicles (EVs) | IV | Native | II/III | Recruiting |
| NCT04355728 | Use of UC‐MSCs for COVID‐19 patients | Umbilical cord MSC | 100 × 106 cells | IV | Native | I/ II | Completed |
| NCT04362189 | Efficacy and safety study of allogeneic HB‐adMSCs for the treatment of COVID‐19 | Adipose MSC | 100 × 106 cells | IV | Native | II | Not yet recruiting |
| NCT04392778 | Clinical use of stem cells for the treatment of COVID‐19 | Adipose MSC | 3 × 106 cells/kg | IV | Native | I/ II | Recruiting |
| NCT04299152 | Stem cell educator therapy treat the viral inflammation in COVID‐19 | Cord blood stem cells | Not mentioned | IV | Native | II | Not yet recruiting |
| NCT04390152 | Safety and efficacy of intravenous Wharton's jelly derived mesenchymal stem cells in acute respiratory distress syndrome due to COVID‐19 | Wharton's jelly MSC | 50 × 106 | IV | Native | I/ II | Not yet recruiting |
| NCT04293692 | Therapy for pneumonia patients infected by 2019 novel coronavirus | Bone marrow MSC | 0.5 × 106/kg | IV | Native | Not applicable | Withdrawn |
| NCT04348461 | Battle against COVID‐19 using mesenchymal stromal cells | Bone marrow MSC | 1.5 × 106/kg | IV | Native | II | Not yet recruiting |
| NCT04331613 | Safety and Efficacy of CAStem for severe COVID‐19 associated with/without ARDS | Embryonic stem cells | 3, 5 or 10 × 106 cells/kg | IV | Native | I/ II | Recruiting |
| NCT04377334 | MSCs in inflammation‐resolution programs of coronavirus disease 2019 (COVID‐19) induced ARDS | Bone marrow MSC | Not mentioned | IV | Native | II | Not yet recruiting |
| NCT04371393 | MSCs in COVID‐19 ARDS | Bone marrow MSC | 2 × 106/kg | IV | Native | III | Recruiting |
| NCT04341610 | ASC therapy for patients with severe respiratory COVID‐19 | Adipose MSC | 100 × 106 | IV | Native | I/II | Withdrawn |
| NCT04390139 | Efficacy and safety evaluation of mesenchymal stem cells for the treatment of patients with respiratory distress due to COVID‐19 | Wharton‐Jelly MSC | 1 × 106 cells/Kg | IV | Native | I/ II | Recruiting |
| NCT04400032 | Cellular immuno‐therapy for COVID‐19 acute respiratory distress syndrome – Vanguard | Bone marrow MSC | 75 × 106 | IV | Native | II | Not yet recruiting |
| NCT04398303 | ACT‐20 in patients with severe COVID‐19 pneumonia | Umbilical cord MSC | 1 × 106 cells/kg | IV | Native | I/ II | Not yet recruiting |
| NCT04397796 | Study of the safety of therapeutic Tx with immunomodulatory MSC in adults with COVID‐19 infection requiring mechanical ventilation | Bone marrow MSC | Not mentioned | IV | Modified | I | Not yet recruiting |
| NCT04393415 | Using PRP and cord blood in treatment of COVID‐19 | Umbilical cord MSC | Not mentioned | IV | Native | Not applicable | Recruiting |
| NCT03042143 | Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) (COVID‐19) | Umbilical cord MSC | 400 × 106 | IV | Native | I/ II | Recruiting |
| NCT04345601 | Mesenchymal stromal cells for the treatment of SARS‐CoV‐2 induced acute respiratory failure (COVID‐19 Disease) | Bone marrow MSC | 2 × 106 cells/kg | IV | Native | I | Not yet recruiting |
| NCT04361942 | Treatment of severe COVID‐19 pneumonia with allogeneic mesenchymal stromal cells (COVID_MSV) | Bone marrow MSC | 1 × 106/kg | IV | Modified | II | Recruiting |
| NCT04269525 | Umbilical cord (UC)‐derived mesenchymal stem cells (MSCs) treatment for the 2019‐novel coronavirus pneumonia | Umbilical cord MSC | 3.3 × 1067 | IV | Native | II | Recruiting |
| NCT04333368 | Cell therapy using umbilical cord‐derived mesenchymal stromal cells in SARS‐CoV‐2‐related ARDS | Umbilical cord MSC | 1 × 106/kg | IV | Native | I/ II | Not yet recruiting |
| NCT04389450 | Double‐blind, multicenter, study to evaluate the efficacy of PLX PAD for the treatment of COVID‐19 | Placental MSC | Not mentioned | IV | Modified | II | Recruiting |
| NCT04367077 | MultiStem administration for COVID‐19 induced ARDS (MACoVIA) | Multistem MSC | Not mentioned | IV | Modified | II/III | Recruiting |
| NCT04276987 | A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia | MSCs‐derived exosomes | 2 × 108 nano vesicles | IV | Native | I | Completed |
Abbreviations: ARDS, Acute respiratory distress syndrome; ASC, Apoptosis‐associated speck‐like protein containing a CARD; MSC, mesenchymal stem cells; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.